2Shalev A, Harmesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiat, 1989,50 (I) :18 -25.
3Pope H, Keck P, MeElroy S. Frequency and presentation of neuroleptie malignant syndrome in a large psychiatric hospital. Am J Psychiat,1986, 143(10) :1227 - 1233.
4Hasan S, Buckley P. Novel Antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiat, 1998, 155 (8) :1113 - 1116.
5Strawn JR. Aripiprazole and the neuroleptic malignant syndrome. Schizophr Res, 2006,85 ( 1 - 3 ) : 298 - 299.
6Sachdev PS. A rating scale for neuroleptic malignant syndrome. Psychiatry Res, 2005,135 (3) :249 - 256.
7Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiat,2007,164 (6) : 870 - 876.
8Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. CMAJ, 2003, 169 (5):439 - 442.
9Stubner S, Rustenbeck E, Grohmann R, et al. Severe and uneoinmon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry, 2004, 37 ( suppl 1 ) :54 - 64.
10Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiat, 1999,156 ( 2 ) : 169 - 180.
